Orchestra BioMed (NASDAQ:OBIO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...

Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to ...

BTIG Research initiated coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.

BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed (OBIO) with a Buy rating and $12 price target Orchestra is a medical ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT ...

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company ...

NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company ...

Orchestra Biomed's latest twelve months ebitda is -59.809 million Orchestra Biomed's ebitda hit its 5-year low in December 2023 of -51.219 million. Orchestra Biomed's ebitda decreased in 2021 (-21.618 ...

Additionally, Orchestra BioMed will conduct one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025. Engagement and Accessibility ...